Diabetes is rising at an alarming rate in the United States
Between the year 2000 and 2019, the number of people living with diabetes tripled and the number of new cases annually (incidence) doubled in the United States.
The United States represents the third-largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels in 2018.
The United States Diabetes Market is expected to reach US$ 26.28 billion by the year 2025
The use of continuous glucose monitoring systems and continuous subcutaneous insulin infusion has gained full acceptance in diabetes care.
These devices have demonstrated to be clinically valuable, reducing risks of hypoglycemia and improving glycemic control in ambulatory patients with type 1 diabetes & type 2 diabetes.
Because of this tremendous improvement in the number of patients, especially that requiring insulin therapy, the cost of healthcare-related to diabetes and its complications is ever increasing.
The market of Insulin Pen, Insulin Pump, Continuous Glucose Monitoring (CGM) Device and Self Monitoring Blood Glucose Device are growing due to the rise in numbers of diabetic patients in the United States.
The increasing diabetes prevalence has led the U.S. Government to launch diabetes to raise awareness and prevention programs about its symptoms and encourage healthier lifestyle behaviour amongst the citizens.
In 2019, Abbott Laboratories planned to ramp up manufacturing capacity for its lower-cost continuous glucose monitor (CGM) device in the next few years, targeting to reach millions of more patients worldwide, According to Reuters.
In March 2018, Sanofi-aventis U.S. LLC received approval from the U.S. Food and Drug Administration for Toujeo Max SoloStar.
- B. Braun Melsungen AG
- Eli Lilly and Company
- Artsana S.p.A.
- Novo Nordisk A/S
- Owen Mumford Ltd.
- Ypsomed AG
- Insulet Corporation
- LifeScan Inc.
- Abbott Laboratories
For more information about this report visit https://www.researchandmarkets.com